


I hereby certify that this correspondence is being deposited with the United States Postal Service on the date indicated below as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit: 5 March 2001

Typed Name: Carolyn C. Cairns

Signature: Carolyn C. Cairns



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventors: Riser and DeNichilo

Title: METHODS FOR DETECTING,  
PREVENTING, AND TREATING  
RENAL DISORDERS BY  
MODULATING, REGULATING,  
AND INHIBITING CONNECTIVE  
TISSUE GROWTH FACTOR

Confirmation No.: 9469

U.S. Serial No.: 09/392,024

Filing Date: 8 September 1999

Examiner: P. Nolan

Group Art Unit: 1644

---

Assistant Commissioner for Patents  
Washington, D.C. 20231

**SEQUENCE LISTING STATEMENT UNDER 37 C.F.R. 1.821(f)**

Sir:


Accompanying this statement is a diskette that contains a computer readable form copy of the Sequence Listing for the above-referenced application. The Sequence Listing is understood to comply with the requirements of 37 C.F.R. 1.821 through 1.824. The content of the computer readable copy is the same as that of the paper copy of the Sequence Listing submitted in the above-referenced case.

Please contact Applicants' Attorney with any questions regarding this communication.

Date:

6 March 01

Respectfully submitted,



Leanne C. Price, Esq.

Reg. No. 42,090

FibroGen, Inc.  
225 Gateway Boulevard  
South San Francisco, CA 94080  
Main: 650-866-7200  
Direct: 650-866-7254  
Facsimile: 650-866-7204

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**